Foam preparations for the treatment of XXXX .

@entity1 @entity32 @entity31 @entity5584 @entity694 @entity2983 @entity288
@entity1 with @entity31 uniformly have disease involving the distal colon. When @entity1 have disease limited to the left colon or symptoms suggestive of @entity32 , guidelines recommend topical rectal therapies as first-line agents either as monotherapy or in conjunction with oral products. Rectal delivery modalities offer the advantage of delivering high local concentrations of active medication to the site of maximal inflammation with minimization of systemic side effects. Methods of rectal administration include suppositories, liquid enemas and foams. Suppositories are limited to the treatment of @entity5584 , and @entity1 often have difficulty retaining the liquid enema secondary to its high volume and consistency. Rectal foams reliability extend to the descending and sigmoid colon with application. Foams are further characterized by increased viscosity, lower volumes, finer dispersion on the colonic mucosa, and @entity694 compared with liquid enemas. Additionally, rectal foam agents demonstrate equal efficacy to their liquid enema counterparts yet consistently yield better @entity1 tolerance, lower incidence of side effects, and increased @entity1 acceptability. Currently available agents include @entity2983 and @entity288 , both first and newer generation. This review focuses on clinical trials assessing efficacy, tolerability, and @entity1 preferences for these agents as well as describing the currently available rectal foam products.
